This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
Rifampin is an effective antituberculous drug recently approved by the Food and Drug Administration for general use. Users are warned thatRifampin has been shown to produce liver dysfunction. There have been fatalities associated with jaundice in patients with liver disease or receiving rifampin concomitantly with other hepatotoxic agents. Since an increased risk may exist for individuals with liver disease, benefits must be weighed carefully against the risk of further liver damage. Periodic liver function monitoring is mandatory.Ethyl alcohol is probably the most common hepatotoxic agent ingested, and in the quantities consumed by the chronic alcoholic patient its effects are well known. In our hands a widely based alcoholism therapeutic program in which disulfiram plays an important role provides the greatest likelihood that alcohol ingestion will be minimal, and, not infrequently, totally absent.Disulfiram is not hepatotoxic in the usual sense, but does interfere sharply with
Rothstein E. Rifampin With Disulfiram. JAMA. 1972;219(9):1216. doi:10.1001/jama.1972.03190350052029
Customize your JAMA Network experience by selecting one or more topics from the list below.